US regulators have expanded the label for Vertex’s cystic fibrosis drug, Kalydeco, extending its use to include children aged 12-24 months with certain genetic mutations. The FDA said Kalydeco ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback